US FDA approves Mesoblast’s mesenchymal stromal cell therapy, Ryoncil for steroid-refractory aGvHD in children 2 months and older: Melbourne, Australia Monday, December 23, 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback